Clinical trial NCT02295267: Molecular Analysis of IgE Antibodies in Walnut Allergic Patients
Official title: Molecular Analysis of IgE Antibodies in Walnut Allergic Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Food Allergy
Keywords: Food allergy
Walnut
Components
Allergens
Lead sponsor: University of Zurich
Sponsor class: OTHER
Collaborators: name: Paul Ehrlich Institute Langen
name: Hospital Clinic of Barcelona
name: St. Marien Hospital Bonn
name: Thermo Fisher Scientific, Inc
First posted: 2014-11-20
Enrollment: 61
Sex: ALL
Minimum age (years): 1
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Accurate diagnosis of food allergy depends on the identification of the causative allergenic molecule(s). The proposed study intends to investigate and compare the pattern of IgE antibody sensitisation in walnut allergic subjects from three different regions of Europe (south (SEU) and central/north (C/NEU), to evaluate the diagnostic utility of a panel of novel allergen reagents.

Detailed description: Accurate diagnosis of food allergy depends on the identification of the causative allergenic molecule(s). Thus, full characterization of the major allergens of walnut and their clinical importance is an important undertaking.

The proposed study intends to investigate and compare the pattern of IgE antibody sensitisation in walnut allergic subjects from three different regions of Europe (south (SEU) and central/north (C/NEU), to evaluate the diagnostic utility of a panel of novel allergen reagents.

With a view towards improved in vitro diagnostic methods, we intend to evaluate the diagnostic potential of recombinant walnut allergens in patients with walnut allergy confirmed by a positive provocation or supported by a convincing history of anaphylactic reaction(s) to walnut in the past, patients with pollinosis but no symptoms of walnut allergy and non-atopic control subjects.

Eligibility criteria: Inclusion Criteria:

* Signed informed consent
* Group A: positive case history of allergic reaction(s) to walnut
* Group B: positive case history of allergy to birch, grass or olive pollen and no case history of allergic reaction(s) to walnut
* Group C: no case history of atopic disease

Exclusion Criteria:

* Known pregnancy
* Breast-feeding of infant
* Treatment with the following drugs (or shortest interval between last treatment and food challenge or SPT):
* corticosteroids (2 weeks): applied systemically, to the nose or locally on the skin test area.
* antihistamines (3 days) except hydroxyzine (10 days)
* betablocker agents (1 day)
* angiotensin converting enzyme inhibitors (2 days)
* Any major organic or infectious disease

Primary outcomes:
measure: numbers of patients with walnut allergy
timeFrame: December 2012 to November 2017, up to 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Zürich
country: Switzerland
facility: Allergy Unit, Department of Dermatology, University Hospital
Study officials:
affiliation: Allergy Unit, Department of Dermatology, University Zürich
name: Barbara Ballmer-Weber, PI
role: PRINCIPAL_INVESTIGATOR
References: